Aqueous Interleukin-6 (IL-6) Level Is a Marker for Treatment Resistance to Bevacizumab in Age-Related Macular Degeneration —Aqueous Cytokines after Bevacizumab

Chalam, Kakarla V.; Grover, Sandeep; Balaiya, Sankarathi; Murthy, Ravi

doi:10.4236/ojoph.2014.41005

Cited by 1 publication

(1 citation statement)

References 22 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical administration (as opposed to intravitreal injection) may reduce the risk for adverse events, such as endophthalmitis, infection, and eye irritation. Finally, a study by Chalam et al 62 found that interleukin 6 levels correlate with resistance to anti-VEGF treatment in AMD, further increasing the need for alternative interventions. Taken together, topical minocycline and/or DAM eye drops may represent a promising new treatment strategy for CNV-related disorders.…”

Section: Discussionmentioning

confidence: 99%

Minocycline and Diacetyl Minocycline Eye Drops Reduce Ocular Neovascularization in Mice

Willms,

Mitchell,

Shashtri

et al. 2023

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose To evaluate the efficacy of minocycline and a novel, modified minocycline analogue that lacks antimicrobial action, diacetyl minocycline (DAM), on choroidal neovascularization (CNV) in mice of both sexes. Methods CNV was induced via laser injury in female and male C57BL/6J mice. Minocycline, DAM, or saline was administered via topical eye drops twice a day for 2 weeks starting the day after laser injury. CNV volume was measured using immunohistochemistry labeling and confocal microscopy. Results Minocycline reduced lesion volume by 79% ( P ≤ 0.0004) in female and male mice. DAM reduced lesion volume by 73% ( P ≤ 0.001) in female and male mice. There was no significant difference in lesion volume between minocycline and DAM treatment groups or between female and male mice. Conclusions Both minocycline and DAM eye drops significantly reduced laser-induced CNV lesion volume in female and male mice. While oral tetracyclines have been shown to mitigate pathologic neovascularization in both preclinical studies and clinical trials, the present data are the first to suggest that tetracycline derivatives may be effective to reduce pathologic CNV when administered via topical eye drops. However, the action is unrelated to antimicrobial action. Targeted delivery of these medications via eye drops may reduce the potential for systemic side effects. Translational Relevance Topical administration of minocycline and/or DAM via eye drops may represent a novel therapeutic strategy for disorders involving pathologic CNV.

show abstract

Section: Discussionmentioning

confidence: 99%